kainos loboratories,inc Logo

kainos loboratories,inc

Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.

4556 | T

Overview

Corporate Details

ISIN(s):
JP3205650009
LEI:
Country:
Japan
Address:
文京区本郷二丁目38番18号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kainos Laboratories, Inc., founded in May 1975, is a company engaged in the research, development, manufacturing, and sale of clinical diagnostic products. It specializes in innovative clinical testing reagents, including biochemical and immunochemistry diagnostics, and also handles pharmaceuticals. The company's operations encompass the entire product lifecycle, from R&D to marketing, distribution, and import/export activities. Kainos Laboratories positions itself as a pioneer in its field, focused on creating innovative medical diagnostic tools for the healthcare industry.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 02:17
Registration Form
確認書
Japanese 8.1 KB
2025-11-06 02:16
Interim Report
半期報告書-第51期(2025/04/01-2026/03/31)
Japanese 157.7 KB
2025-06-20 03:02
Governance Information
内部統制報告書-第50期(2024/04/01-2025/03/31)
Japanese 21.9 KB
2025-06-20 03:00
Registration Form
確認書
Japanese 8.1 KB
2025-06-20 02:59
Annual Report
有価証券報告書-第50期(2024/04/01-2025/03/31)
Japanese 710.6 KB
2025-06-20 02:56
Post-Annual General Meeting Information
臨時報告書
Japanese 23.6 KB
2024-11-06 01:39
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-11-06 01:38
Interim Report
半期報告書-第50期(2024/04/01-2025/03/31)
Japanese 160.1 KB
2024-06-21 03:08
Post-Annual General Meeting Information
臨時報告書
Japanese 22.5 KB
2024-06-21 03:06
Governance Information
内部統制報告書-第49期(2023/04/01-2024/03/31)
Japanese 21.1 KB
2024-06-21 03:04
Registration Form
確認書
Japanese 8.1 KB
2024-06-21 03:02
Annual Report
有価証券報告書-第49期(2023/04/01-2024/03/31)
Japanese 704.8 KB
2024-02-02 01:39
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-02-02 01:38
Quarterly Report
四半期報告書-第49期第3四半期(2023/10/01-2023/12/31)
Japanese 135.5 KB
2023-11-02 02:27
Report Publication Announcement
確認書
Japanese 8.0 KB

Automate Your Workflow. Get a real-time feed of all kainos loboratories,inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for kainos loboratories,inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for kainos loboratories,inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.